2025三季度财报发布，膳食营养补充剂（VDS）龙头企业汤臣倍健交出复苏答卷：营收、净利润同比双增，第三 季度营收同比增长23.45%，且前三季度利润同比恢复增长，经营能力逐季改善。 汤臣倍健董事长梁允超在30周年庆典上说道："不在'品牌和产品创新'的餐桌上，就在'渠道'的菜单上。"业绩修复 的背后，是一场以用户价值为核心、贯穿研发、品牌、渠道全链路的价值链深度变革，更是汤臣倍健从行业变局 中探索新增长路径的必然结果。 行业重构期，锚定用户价值打破迷局 面对消费变局，不同行业都在求突围，但唯有企业经营数据才是见真章的"试金石"。 汤臣倍健的改革，不是为了应对业绩下跌的临时之举，而是长期主义战略的延续和深化。 VDS行业增速放缓，线下药店作为传统基本盘，一边受医保政策影响，一边面临客流下滑，品牌和渠道不再紧密 合作，反而变成利益博弈；线上渠道则陷入低价、同质化混战，企业盈利空间被挤压。 与此同时，消费需求在升级。普通消费者看重"同价位里品质最好"的质价比，高端用户则愿意为"实打实的科学功 能"和专业价值买单。过去那种"一刀切"的产品供给，跟不上市场需求的分化节奏。 危中有机，行业结构性机会依然清晰。2024年中 ...

Core Insights - The core viewpoint of the article emphasizes that the operational data of companies serves as a true measure of their performance amidst changing consumer dynamics, with Tongrentang's (汤臣倍健) recent financial results showcasing a recovery in revenue and net profit [1][12] Group 1: Company Performance - Tongrentang reported a 23.45% year-on-year increase in revenue for Q3 2025, with profits also showing recovery in the first three quarters [1][12] - The company launched 71 new products in the first three quarters of 2025 and holds 487 domestic and international patents, indicating a strong focus on innovation [4][12] Group 2: Strategic Transformation - The company's reform is a continuation of its long-term strategy rather than a temporary response to declining performance, focusing on user value and breaking away from past dependencies [3][12] - Tongrentang's "strong technology transformation" strategy aims to enhance product strength and technological competitiveness, with a commitment to user needs as the core of its growth path [3][4] Group 3: Market Dynamics - The VDS industry is experiencing a slowdown, with traditional offline pharmacies facing challenges from policy changes and reduced foot traffic, while online channels are struggling with price wars and homogenization [3][6] - Despite these challenges, the VDS market is projected to grow by 3.7% in 2024, outpacing the 1.7% growth of the fast-moving consumer goods market [3] Group 4: Product and Channel Strategy - Tongrentang is building a dual-engine product matrix of "basic mass products + segmented functional products" to address both general market needs and specialized high-value areas [9][10] - The company is shifting its channel strategy from a focus on quantity to a model of empowerment and profit-sharing, enhancing collaboration with pharmacies and leveraging digital tools for efficient operations [10][11] Group 5: Brand Positioning - Tongrentang is enhancing its brand image through partnerships in scientific exploration and health initiatives, reinforcing its trust and credibility in the market [11][12] - The company aims to create a complete value chain centered on user health, integrating R&D, branding, and channels to meet real consumer needs [12][13]

Core Insights - Tongrentang's Q3 2025 report shows a revenue of 1.383 billion yuan, a year-on-year increase of 23.45%, with a net profit of 170 million yuan for the quarter and a total revenue of 4.915 billion yuan and net profit of 907 million yuan for the first three quarters [1][2] Group 1: Product Innovation and Strategy - Since 2025, the company has focused on product innovation, launching 71 new products in the first three quarters, with a dual strategy of upgrading basic nutrients and breaking into professional functional categories [1][2] - The company has extended its product line into high-barrier functional categories, launching its first OTC glucosamine product offline and a special medical purpose formula food online in September [1] Group 2: Channel Strategy and Market Performance - Tongrentang has implemented a differentiated product strategy for online and offline channels, optimizing the channel value chain, with improvements in operational quality [2] - The company has seen significant performance in e-commerce, with new products like multi-layer tablets and adult calcium series driving market share growth [2] Group 3: R&D and Compliance - Under the "Scientific Nutrition" strategy, the company has advanced R&D in new materials, functions, and technologies, holding 487 patents and numerous health food certifications, indicating strong technical reserves and compliance capabilities [2] - Systematic adjustments across products, channels, R&D, and branding since 2024 have shown quick reform results, demonstrating the company's operational resilience [2]

Core Insights - The company reported a significant increase in revenue and net profit for Q3 2025, with revenue reaching 1.383 billion yuan, a year-on-year growth of 23.45%, and net profit of 170 million yuan, marking a remarkable year-on-year increase of 861.91% [2] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 4.915 billion yuan and a net profit of 907 million yuan, indicating a recovery in profitability and operational capability [2] - The company has shown consistent improvement in its financial metrics, with both revenue and profit increasing year-on-year [2] Product Innovation and Strategy - The company has focused on product innovation as a key strategy, launching 71 new products in the first three quarters of 2025 [2] - The product strategy includes a dual approach of upgrading basic nutrients and breaking into specialized functional categories, which strengthens its presence in the mass consumer market while also targeting professional sectors [2][3] Market Demand and Consumer Engagement - The company has effectively driven category growth in the basic nutrient sector by promoting high cost-performance products, which has broadened its customer base [3] - New products such as the adult calcium series with high vitamin K2 content have led to a 48% growth in the liquid calcium category on e-commerce platforms [3] Channel Strategy - The company has implemented a differentiated inventory strategy to optimize the value chain across online and offline channels, with positive results beginning to show [4] - In offline channels, the company has improved its market share in the protein powder category by 3.3 percentage points year-on-year, driven by products like calcium vitamin E protein powder [4] Research and Development - The company has made significant advancements in R&D, holding 487 patents and numerous certifications for health food products, positioning itself at the forefront of the industry [5] - The company has also established partnerships for scientific exploration, enhancing its brand image and credibility in the market [5] Future Outlook - Following a period of adjustment, the company is expected to stabilize and recover, laying a solid foundation for long-term growth as new products continue to be released and operational efficiency improves [6]

Core Insights - The company reported a significant increase in both revenue and net profit for the third quarter of 2025, with revenue reaching 1.383 billion yuan and net profit at 170 million yuan, marking a year-on-year profit growth of 861.91% [1] - For the first three quarters of 2025, total revenue was 4.915 billion yuan, with a net profit of 907 million yuan, indicating a recovery in profitability and operational capability [1][5] Product Innovation - The company has focused on product innovation as a key strategy, launching a total of 71 new products in the first three quarters of 2025 [3] - The product strategy includes a dual approach of upgrading basic nutrients and breaking into specialized functional categories, which strengthens the consumer market while expanding into professional fields [3] - Notable product launches include a high-content vitamin K2 adult calcium series, which drove a 48% growth in the liquid calcium category, and a multi-layer tablet that continues to boost category growth [3] Channel Strategy - The company has implemented a differentiated inventory strategy to optimize the value chain across online and offline channels, with positive adjustments becoming evident [4] - In offline channels, the company has improved market share in the protein powder category by 3.3 percentage points, driven by the calcium vitamin E protein powder [4] - Online, the company has focused on professional, segmented, and high-end upgrades, with new products performing well on e-commerce platforms, including a new high-content vitamin K2 liquid calcium series targeting specific demographics [4] Research and Development - The company has made significant advancements in research and development, holding 487 patents and numerous certifications for health food products, positioning itself at the forefront of the industry [5] - The company has also enhanced its brand image by becoming a partner in significant scientific exploration projects, further establishing its professional reputation [5] Overall Performance - Following a challenging year in 2024, the company has shown resilience through systematic adjustments across various dimensions, achieving notable reform results in a short time [5] - The ongoing release of new products and improvements in operational efficiency are expected to stabilize and support long-term growth [5]

Core Viewpoint - The company is facing significant challenges and aims to adopt a "re-entrepreneurial" mindset to achieve new revenue highs from 2026 to 2028, outperforming industry growth rates across all channels [2][5][11]. Group 1: Company Strategy and Goals - The company plans to complete a digital infrastructure for pharmacies and explore new business models to create greater value for consumers and partners [10]. - From 2026 to 2028, the company aims to achieve revenue growth that surpasses the growth rates of the VDS category, focusing on various channels including traditional e-commerce and international markets [11][18]. - The company emphasizes the importance of product innovation, with a focus on new functional products and dosage forms, aiming for a significant portion of new product sales to exceed 20% in 2025 [12]. Group 2: Market Challenges and Opportunities - The company acknowledges missing the opportunity to capitalize on the new cycle of dietary supplements in 2023, which has led to significant setbacks [4][5]. - External factors such as healthcare policies and declining purchasing power have negatively impacted the VDS category, while internal factors include the lack of growth in key channels [5][6]. - The company recognizes that the current challenges present opportunities for growth and innovation, stating that crises can lead to new opportunities [8][9]. Group 3: Brand and Innovation Focus - The company is committed to investing in brand development and product innovation, even at the cost of short-term profits, as brand strength is seen as a core competitive advantage [14][15]. - The company aims to leverage AI technology to enhance product offerings and ensure that scientific nutrition remains a focal point in the market [13][20]. - The company is also focused on expanding its global market presence and fostering new growth engines through innovative projects [15].